Sponsored by:

**Nuclear Medicine- Table of Contents**

Scott Williams
Apr 2, 2002

**Nuclear Medicine- Table of Contents**

Scott C. Williams, MD

 Contributors

General Nuclear Medicine

Cardiac Imaging

Central Nervous System

Endocrine: Thyroid & Parathyroid

Genitourinary

Gastrointestinal

Infection and Inflammation

Musculoskeletal: Bone/Soft Tissues and Lymphatics

Positron Emission Tomography (PET)

Pulmonary

Tumor Imaging and Radionuclide Therapy

Radioscintigraphic Assay and Volumetry (RIA)

Radiation Biology

(C) 1995-2024 Scott Williams, M.D.
Latest in Nuclear Medicine
Nuclearmedicine
IU Health launches theranostics center
August 19, 2026
Research Money 400
Radnostix reports revenue decline in Q2
August 13, 2026
Advancing molecular imaging together
Sponsored
Advancing molecular imaging together
May 24, 2026
Cerenome
Plus Therapeutics rebrands as Cerenome
August 3, 2026
Related Stories
Whole Body
Nuclear Medicine
Prostascint (111In-Capromab Pendetide) (CYT-356)
Primary Ct
Nuclear Medicine
PET > PET tumor imaging > Breast Cancer
Lsegs
Nuclear Medicine
Pulmonary
Advancing molecular imaging together
Sponsor Content
Advancing molecular imaging together
More in Nuclear Medicine
IU Health launches theranostics center
By AuntMinnie.com staff writers
The center is supported by a $40 million commitment.
August 19, 2026
Nuclearmedicine
Radnostix reports revenue decline in Q2
By AuntMinnie.com staff writers
The company attributed the revenue dip to two voluntary product recalls and the Cobalt-60 hot-cell shutdown.
August 13, 2026
Research Money 400
ITM receives Complete Response Letter for ITM-11
By AuntMinnie.com staff writers
The FDA stated that it's unable to approve the NDA in its present form.
August 10, 2026
Nuclear Medicine
Plus Therapeutics rebrands as Cerenome
By AuntMinnie.com staff writers
The move reflects the company's evolution from a therapeutics-focused organization into an integrated central nervous system (CNS) oncology company.
August 3, 2026
Cerenome
Novartis secures expanded approval for Pluvicto
By AuntMinnie.com staff writers
Pluvicto can now be used as therapy in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, in combination with an androgen receptor pathway inhibitor.
July 31, 2026
Prostate Imaging
SNMMI issues analysis of 2027 HOPPS proposed rule
By AuntMinnie.com staff writers
The proposed rule includes several positive code-level changes for nuclear medicine providers.
July 29, 2026
Snmmi
ITM launches new oncology therapeutics division
By AuntMinnie.com staff writers
Lumara Bio will focus resources toward commercial readiness for ITM's lead drug candidate, lutetium-177 (Lu-177) edotreotide (ITM-11).
July 27, 2026
Lumara
Lutetium-177 PSMA-617 shows promise in earlier-stage prostate cancer
By Will Morton
Across 14 studies, PSA50 response rates (the number of patients with at least a 50% drop in PSA) ranged from 44% to 100%.
July 21, 2026
Prostate Imaging
GE HealthCare introduces MIM Anyware remote access platform
By AuntMinnie.com staff writers
The platform allows authorized users to access MIM software applications from any location without local installation.
July 21, 2026
Ge Health Care Logo New March 2023
AdvanCell raises $315M for targeted alpha therapy
By AuntMinnie.com staff writers
The company is developing ADVC001, a lead-212 (Pb-212)-based targeted alpha therapy for metastatic prostate cancer.
July 15, 2026
Cash Bills
Nucs AI, Segmed to build AI validation platform for theranostics
By AuntMinnie.com staff writers
The companies will develop disease-specific registries, curated research cohorts, and validation frameworks.
July 14, 2026
Artificial Intelligence Ai 400
Actineer completes Ra-226 recycling process to support Ac-225 supply
By AuntMinnie.com staff writers
This process aims to improve Ac-225 supply predictability and cost stability, as well as reduce waste generation.
July 14, 2026
Nuclear Medicine Worker Sm
Page 1 of 444
Next Page